Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction in Israel. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis. It develops Namodenoson that is in Phase III clinical trial for the treatment of liver cancer; and Phase IIa for the treatment of pancreatic cancer; as well as in Phase IIb trial for the treatment of metabolic associated steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, the company develops commercial predictive biomarker blood test kit for A3AR. It has license and collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and collaboration agreement with Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. The company was incorporated in 1994 and is headquartered in Ramat Gan, Israel. more
Time Frame | CANF | Sector | S&P500 |
---|---|---|---|
1-Week Return | -2.41% | 0.31% | -1.26% |
1-Month Return | 7.28% | 0.6% | -4.16% |
3-Month Return | -35.71% | -9.44% | -0.46% |
6-Month Return | -51.93% | -5.15% | 3.58% |
1-Year Return | -18.59% | 0.33% | 22.47% |
3-Year Return | -87.63% | 4.53% | 25.13% |
5-Year Return | -93.96% | 35.98% | 77.7% |
10-Year Return | -99.71% | 100.72% | 190.12% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 2.03M | 763.00K | 853.00K | 810.00K | 743.00K | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":37.55,"profit":true},{"date":"2021-12-31","value":41.98,"profit":true},{"date":"2022-12-31","value":39.86,"profit":true},{"date":"2023-12-31","value":36.56,"profit":true}] |
Cost of Revenue | 51.00K | - | - | - | 15.00K | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":29.41,"profit":true}] |
Gross Profit | 2.03M | 763.00K | 853.00K | 810.00K | 743.00K | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":37.55,"profit":true},{"date":"2021-12-31","value":41.98,"profit":true},{"date":"2022-12-31","value":39.86,"profit":true},{"date":"2023-12-31","value":36.56,"profit":true}] |
Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Expenses | 14.04M | 14.90M | 13.70M | 10.91M | 8.94M | [{"date":"2019-12-31","value":94.21,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":91.9,"profit":true},{"date":"2022-12-31","value":73.18,"profit":true},{"date":"2023-12-31","value":59.98,"profit":true}] |
Operating Income | (12.01M) | (14.14M) | (12.84M) | (10.10M) | (8.20M) | [{"date":"2019-12-31","value":-1200700000,"profit":false},{"date":"2020-12-31","value":-1413900000,"profit":false},{"date":"2021-12-31","value":-1284200000,"profit":false},{"date":"2022-12-31","value":-1009600000,"profit":false},{"date":"2023-12-31","value":-819500000,"profit":false}] |
Total Non-Operating Income/Expense | (1.00M) | (646.00K) | 229.00K | (154.00K) | 1.29M | [{"date":"2019-12-31","value":-77.86,"profit":false},{"date":"2020-12-31","value":-50.19,"profit":false},{"date":"2021-12-31","value":17.79,"profit":true},{"date":"2022-12-31","value":-11.97,"profit":false},{"date":"2023-12-31","value":100,"profit":true}] |
Pre-Tax Income | (12.63M) | (14.44M) | (12.62M) | (10.17M) | (7.63M) | [{"date":"2019-12-31","value":-1262500000,"profit":false},{"date":"2020-12-31","value":-1444300000,"profit":false},{"date":"2021-12-31","value":-1261500000,"profit":false},{"date":"2022-12-31","value":-1017300000,"profit":false},{"date":"2023-12-31","value":-763400000,"profit":false}] |
Income Taxes | 427.00K | 363.00K | (20.00K) | 63.00K | 1.00 | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":85.01,"profit":true},{"date":"2021-12-31","value":-4.68,"profit":false},{"date":"2022-12-31","value":14.75,"profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Income After Taxes | (13.05M) | (14.81M) | (12.60M) | (10.24M) | (7.63M) | [{"date":"2019-12-31","value":-1305200000,"profit":false},{"date":"2020-12-31","value":-1480600000,"profit":false},{"date":"2021-12-31","value":-1259500000,"profit":false},{"date":"2022-12-31","value":-1023600000,"profit":false},{"date":"2023-12-31","value":-763400100,"profit":false}] |
Income From Continuous Operations | (9.59M) | (14.44M) | (12.62M) | (10.17M) | (9.00M) | [{"date":"2019-12-31","value":-958700000,"profit":false},{"date":"2020-12-31","value":-1444300000,"profit":false},{"date":"2021-12-31","value":-1261500000,"profit":false},{"date":"2022-12-31","value":-1017300000,"profit":false},{"date":"2023-12-31","value":-900100000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (13.05M) | (14.44M) | (12.60M) | (10.24M) | (7.63M) | [{"date":"2019-12-31","value":-1305200000,"profit":false},{"date":"2020-12-31","value":-1444300000,"profit":false},{"date":"2021-12-31","value":-1259500000,"profit":false},{"date":"2022-12-31","value":-1023600000,"profit":false},{"date":"2023-12-31","value":-763400000,"profit":false}] |
EPS (Diluted) | (45.50) | (17.40) | (8.00) | (3.71) | (3.00) | [{"date":"2019-12-31","value":-4549.55,"profit":false},{"date":"2020-12-31","value":-1740,"profit":false},{"date":"2021-12-31","value":-800,"profit":false},{"date":"2022-12-31","value":-371.03,"profit":false},{"date":"2023-12-31","value":-300,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
CANF | |
---|---|
Cash Ratio | 2.38 |
Current Ratio | 2.93 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
CANF | |
---|---|
ROA (LTM) | -57.46% |
ROE (LTM) | -157.62% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
CANF | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.58 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.42 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
CANF | |
---|---|
Trailing PE | NM |
Forward PE | 2.97 |
P/S (TTM) | 14.81 |
P/B | 3.86 |
Price/FCF | NM |
EV/R | 7.12 |
EV/Ebitda | 0.10 |
PEG | NM |
Can Fite Biopharma Ltd ADR (CANF) share price today is $1.62
Yes, Indians can buy shares of Can Fite Biopharma Ltd ADR (CANF) on Vested. To buy Can Fite Biopharma Ltd ADR from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in CANF stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Can Fite Biopharma Ltd ADR (CANF) via the Vested app. You can start investing in Can Fite Biopharma Ltd ADR (CANF) with a minimum investment of $1.
You can invest in shares of Can Fite Biopharma Ltd ADR (CANF) via Vested in three simple steps:
The 52-week high price of Can Fite Biopharma Ltd ADR (CANF) is $4.69. The 52-week low price of Can Fite Biopharma Ltd ADR (CANF) is $1.29.
The price-to-earnings (P/E) ratio of Can Fite Biopharma Ltd ADR (CANF) is
The price-to-book (P/B) ratio of Can Fite Biopharma Ltd ADR (CANF) is 3.86
The dividend yield of Can Fite Biopharma Ltd ADR (CANF) is 0.00%
The market capitalization of Can Fite Biopharma Ltd ADR (CANF) is $9.88M
The stock symbol (or ticker) of Can Fite Biopharma Ltd ADR is CANF